199 related articles for article (PubMed ID: 23150524)
1. Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos.
van Veenendaal NR; Ulmer B; Boskovski MT; Fang X; Khokha MK; Wendler CC; Blum M; Rivkees SA
FASEB J; 2013 Feb; 27(2):684-91. PubMed ID: 23150524
[TBL] [Abstract][Full Text] [Related]
2. Propylthiouracil is teratogenic in murine embryos.
Benavides VC; Mallela MK; Booth CJ; Wendler CC; Rivkees SA
PLoS One; 2012; 7(4):e35213. PubMed ID: 22529993
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of developmental toxicity of propylthiouracil and methimazole.
Mallela MK; Strobl M; Poulsen RR; Wendler CC; Booth CJ; Rivkees SA
Birth Defects Res B Dev Reprod Toxicol; 2014 Aug; 101(4):300-7. PubMed ID: 24980470
[TBL] [Abstract][Full Text] [Related]
4. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
[TBL] [Abstract][Full Text] [Related]
6. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
Andersen SL; Olsen J; Wu CS; Laurberg P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
[TBL] [Abstract][Full Text] [Related]
7. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
[TBL] [Abstract][Full Text] [Related]
8. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
Kubota S
Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
[TBL] [Abstract][Full Text] [Related]
9. Toxicological considerations for antithyroid drugs in children.
Karras S; Tzotzas T; Krassas GE
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):399-410. PubMed ID: 21323607
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
Huang CN; Hsu TC; Chou HH; Tsay GJ
J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
[TBL] [Abstract][Full Text] [Related]
11. The safety of methimazole and propylthiouracil in pregnancy: a systematic review.
Hackmon R; Blichowski M; Koren G
J Obstet Gynaecol Can; 2012 Nov; 34(11):1077-1086. PubMed ID: 23231846
[TBL] [Abstract][Full Text] [Related]
12. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.
Kimura M; Seki T; Ozawa H; Ishihara T; Komatsu M; Tajiri S; Yanagi H; Nishina M; Noh JY; Fukagawa M; Takagi A
Endocr J; 2013; 60(3):383-8. PubMed ID: 23154533
[TBL] [Abstract][Full Text] [Related]
13. The propylthiouracil dilemma.
Glinoer D; Cooper DS
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):402-7. PubMed ID: 22820213
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.
Gianetti E; Russo L; Orlandi F; Chiovato L; Giusti M; Benvenga S; Moleti M; Vermiglio F; Macchia PE; Vitale M; Regalbuto C; Centanni M; Martino E; Vitti P; Tonacchera M
J Endocrinol Invest; 2015 Sep; 38(9):977-85. PubMed ID: 25840794
[TBL] [Abstract][Full Text] [Related]
15. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
[TBL] [Abstract][Full Text] [Related]
16. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation.
Yoshihara A; Noh J; Yamaguchi T; Ohye H; Sato S; Sekiya K; Kosuga Y; Suzuki M; Matsumoto M; Kunii Y; Watanabe N; Mukasa K; Ito K; Ito K
J Clin Endocrinol Metab; 2012 Jul; 97(7):2396-403. PubMed ID: 22547422
[TBL] [Abstract][Full Text] [Related]
17. Teratogen update: Antithyroid medications.
Romeo AN; Običan SG
Birth Defects Res; 2020 Sep; 112(15):1150-1170. PubMed ID: 32738035
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.
Okamura K; Ikenoue H; Shiroozu A; Sato K; Yoshinari M; Fujishima M
J Clin Endocrinol Metab; 1987 Oct; 65(4):719-23. PubMed ID: 3654917
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
20. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis.
Agrawal M; Lewis S; Premawardhana L; Dayan CM; Taylor PN; Okosieme OE
Clin Endocrinol (Oxf); 2022 Jun; 96(6):857-868. PubMed ID: 34845757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
